Back to Hematology
Hematologyv2019 SanfilippoEvidence-Based

IMPEDE-VTE

Predicts risk of venous thromboembolism (VTE) in patients with multiple myeloma receiving treatment. The IMPEDE-VTE score was developed and validated in large cohorts (4,446 patients in derivation, 4,256 in validation) to identify multiple myeloma patients at highest risk for VTE during treatment. Patients with multiple myeloma have a 9-fold increased risk of VTE compared to the general population. This validated score helps clinicians identify patients who would benefit most from thromboprophylaxis and is incorporated into National Comprehensive Cancer Network (NCCN) guidelines. The model stratifies patients into low, intermediate, and high-risk categories with cumulative 6-month VTE incidences ranging from 3.8-5.0% (low risk) to 24.1-40.5% (high risk) across validation studies.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The IMPEDE-VTE is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Score = (IMiD use: 4 pts) + (BMI ≥25: 1 pt) + (Pelvic/hip/femur fracture: 4 pts) + (ESA use: 1 pt) + (Doxorubicin: 3 pts) + (Dexamethasone low: 2 pts, high: 4 pts) + (Asian/PI ethnicity: -3 pts) + (VTE history: 5 pts) + (Tunneled line/CVC: 2 pts) + (Therapeutic anticoagulation: -4 pts) + (Prophylactic anticoagulation: -3 pts)

Clinical Pearls & Practice Notes

  • Developed from 4,446 multiple myeloma patients in Veterans Administration database
  • Externally validated in 4,256 patients from SEER-Medicare database
  • C-statistic 0.66-0.74 across validation studies demonstrates good discrimination
  • Multiple myeloma patients have 9-fold increased VTE risk vs general population
  • Score incorporated into NCCN Multiple Myeloma Guidelines for VTE risk assessment
  • IMiDs (lenalidomide, thalidomide, pomalidomide) are major VTE risk factors
  • High-dose dexamethasone defined as ≥160mg/month or ≥40mg/week
  • Score outperforms previous IMWG/NCCN risk assessment guidelines
  • Therapeutic anticoagulation includes warfarin or therapeutic-dose LMWH
  • Prophylactic anticoagulation includes prophylactic LMWH or aspirin
  • Consider bleeding risk when selecting thromboprophylaxis agent
  • Duration of thromboprophylaxis should match duration of high-risk treatment
  • Regular reassessment recommended as treatment regimens change
  • Score validated across different ethnic populations including Chinese cohorts

Evidence & Literature Citations

  1. Sanfilippo KM, Luo S, Wang TF, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019 Nov;94(11):1176-1184. doi: 10.1002/ajh.25603.
  2. Sanfilippo KM, Luo S, Wang TF, et al. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. Br J Haematol. 2021 Jun;193(5):1005-1015. doi: 10.1111/bjh.17396.
  3. Li A, Wu Q, Luo S, et al. Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw. 2019 Jul 1;17(7):840-847. doi: 10.6004/jnccn.2018.7273.
  4. National Comprehensive Cancer Network. Multiple Myeloma (Version 3.2023). https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

Score Interpretation Ranges

Low Risk-7 – 3 pts

Score ≤3 points

Intermediate Risk4 – 7 pts

Score 4-7 points

High Risk8 – 19 pts

Score ≥8 points

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.